Unusual thyroid tumors: A review of pathologic and molecular diagnosis

Expert Review of Molecular Diagnostics

Volumn 5, Issue 5, 2005, Pages 725-734

  Hunt, Jennifer L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Anaplastic; Cribriform morular variant; Hyalinizing trabecular tumor; Insular; Mucoepidermoid carcinoma; Papillary carcinoma; Tall cell variant; Thyroid carcinoma

Indexed keywords

B RAF KINASE; EOSIN; HEMATOXYLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN RET; RAS PROTEIN; TRANSCRIPTION FACTOR PAX8;

ADENOSQUAMOUS CARCINOMA; ANAPLASTIC CARCINOMA; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; EOSINOPHILIA; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PAPILLARY CARCINOMA; PATHOGENESIS; POINT MUTATION; REVIEW; THYROID TUMOR; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CELL DIFFERENTIATION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; THYROID NEOPLASMS;

EID: 25144507556     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.5.5.725     Document Type: Review

References (117)

1. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin. Endocrinol. 62, 156-162 (2005).
2. Haselkorn T, Bernstein L, Preston-Martin S, Cozen W, Mack WJ. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995. Cancer Causes Control 11, 163-170 (2000).
3. Merhy J, Driscoll HK, Leidy JW, Chertow BS. Increasing incidence and characteristics of differentiated thyroid cancer in Huntington, West Virginia. Thyroid 11, 1063-1069 (2001).
4. Nasir A, Chaudhry AZ, Gillespie J, Kaiser HE. Papillary microcarcinoma of the thyroid: a clinico-pathologic and prognostic review. In Vivo 14, 367-376 (2000).
5. Price R, Horvath K, Moore FD Jr. Surgery for solitary thyroid nodules: assessment of methods to select patients at low risk for unsuspected malignancy in the unaffected lobe and the possible utility of preoperative thyroid ultrasound. Thyroid 3, 87-92 (1993).
6. Ottino A, Pianzola HM, Castelletto RH. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer 64, 547-551 (1989).
7. Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer 65, 1173-1179 (1990).
8. Hunt JL, LiVolsi VA, Baloch ZW et al. Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile. Am. J. Surg. Pathol. 27, 159-166 (2003).
9. Sanso GE, Domene HM, Garcia R et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia Type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 94, 323-330 (2002).
10. DeLellis RA. Tumors of Endocrine Organs. WHO Classification. IARC, Lyon, France (2004). Updated classification of thyroid tumors, complete with immunohistochemical and molecular data.
11. LiVolsi VA. Hyalinizing trabecular tumor of the thyroid: adenoma, carcinoma, or neoplasm of uncertain malignant potential? Am. J. Surg. Pathol. 24, 1683-1684 (2000).
12. Chetty R, Beydoun R, LiVolsi VA. Paraganglioma-like (hyalinizing trabecular) adenoma of the thyroid revisited. Pathology 26, 429-431 (1994).
13. Carney JA, Ryan J, Goellner JR. Hyalinizing trabecular adenoma of the thyroid gland. Am. J. Surg. Pathol. 11, 583-591 (1987).
14. Sambade C, Franssila K, Cameselle-Teijeiro J, Nesland JM, Sobrinho Simoes M. Hyalinizing trabecular adenoma: a misnomer for a peculiar tumor of the thyroid gland. Endocr. Pathol. 2, 83-91 (1991).
15. Katoh R, Muramatsu A, Kawaoi A et al. Alteration of the basement membrane in human thyroid diseases: an immunohistochemical study of Type IV collagen, laminin and heparan sulfate proteoglycan. Virchows Arch. A Pathol. Anat. Histopathol. 423, 417-424 (1993).
16. Katoh R, Jasani B, Williams ED. Hyalinizing trabecular adenoma of the thyroid. A report of three cases with immunohistochemical and ultrastructural studies. Histopathology 15, 211-224 (1989).
17. Huss LJ, Mendelsohn G. Medullary carcinoma of the thyroid gland: an encapsulated variant resembling the hyalinizing trabecular (paraganglioma-like) adenoma of thyroid. Mod. Pathol. 3, 581-585 (1990).
18. Goellner JR, Carney JA. Cytologic features of fine-needle aspirates of hyalinizing trabecular adenoma of the thyroid. Am. J. Clin. Pathol. 91, 115-119 (1989).
19. Casey MB, Sebo TJ, Carney JA. Hyalinizing trabecular adenoma of the thyroid gland: cytologic features in 29 cases. Am. J. Surg. Pathol. 28, 859-867 (2004).
20. Rothenberg HJ, Goellner JR, Carney JA. Prevalence and incidence of cytoplasmic yellow bodies in thyroid neoplasms. Arch. Pathol. Lab. Med. 127, 715-717 (2003).
21. Rothenberg HJ, Goellner JR, Carney JA. Hyalinizing trabecular adenoma of the thyroid gland: recognition and characterization of its cytoplasmic yellow body. Am. J. Surg. Pathol. 23, 118-125 (1999).
22. Papotti M, Riella P, Montemurro F, Pietribiasi F, Bussolati G. Immunophenotypic heterogeneity of hyalinizing trabecular tumours of the thyroid. Histopathology 31, 525-533 (1997).
23. Hirokawa M, Carney JA, Ohtsuki Y. Hyalinizing trabecular adenoma and papillary carcinoma of the thyroid gland express different cytokeratin patterns. Am. J. Surg. Pathol. 24, 877-881 (2000).
24. Fonseca E, Nesland JM, Sobrinho-Simoes M. Expression of stratified epithelial-type cytokeratins in hyalinizing trabecular adenomas supports their relationship with papillary carcinomas of the thyroid. Histopathology 31, 330-335 (1997).
25. Gaffney RL, Carney JA, Sebo TJ et al. Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland. Am. J. Surg. Pathol. 27, 494-498 (2003).
26. LaGuette J, Matias-Guiu X, Rosai J. Thyroid paraganglioma: a clinicopathologic and immunohistochemical study of three cases. Am. J. Surg. Pathol. 21, 748-753 (1997).
27. Gonzalez-Campora R, Fuentes-Vaamonde E, Hevia-Vazquez A, Otal-Salaverri C, Villar-Rodriguez JL, Galera-Davidson H. Hyalinizing trabecular carcinoma of the thyroid gland: report of two cases of fbllicular cell thyroid carcinoma with hyalinizing trabecular pattern. Ultrastruct. Pathol. 22, 39-46 (1998).
28. Molberg K, Albores-Saavedra J. Hyalinizing trabecular carcinoma of the thyroid gland. Hum. Pathol. 25, 192-197 (1994).
29. McCluggage WG, Sloan JM. Hyalinizing trabecular carcinoma of thyroid gland. Histopathology 28, 357-362 (1996).
30. Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am. J. Surg. Pathol. 24, 1622-1626 (2000). Identification of the Ret/PTC translocation in hyalinizing trabecular tumor, which brought up the possibility that this tumor is a variant of papillary carcinoma.
31. Salvatore G, Chiappetta G, Nikiforov YE et al. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-Raf and N-Ras point mutations. Eur. J. Cancer 41, 816-821 (2005).
32. Lloyd RV. Hyalinizing trabecular tumors of the thyroid: a variant of papillary carcinoma? Adv. Anat. Pathol. 9, 7-11 (2002).
33. Papotti M, Volante M, Giuliano A et al. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am. J. Surg. Pathol. 24, 1615-1621 (2000).
34. Trovisco V, Vieira de Castro I, Soares P et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 202, 247-251 (2004).
35. Baloch ZW, Solomon AC, LiVolsi VA. Primary mucoepidermoid carcinoma and sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: a report of nine cases. Mod. Pathol. 13, 802-807 (2000).
36. Sambade C. Mucoepidermoid carcinoma of the thyroid revisited. Surg. Pathol. 3, 271-280 (1990).
37. Albores-Saavedra J, Gu X, Luna MA. Clear cells and thyroid transcription Factor I reactivity in sclerosing mucoepidermoid carcinoma of the thyroid gland. Ann. Diagn. Pathol. 7, 348-353 (2003).
38. Shehadeh NJ, Vernick J, Lonardo F et al. Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: a case report and review of the literature. Am. J. Otolaryngol. 25, 48-53 (2004).
39. Viciana MJ, Galera-Davidson H, Martin-Lacave I, Segura DI, Loizaga JM. Papillary carcinoma of the thyroid with mucoepidermoid differentiation. Arch. Pathol. Lab. Med. 120, 397-398 (1996).
40. Rocha AS, Soares P, Machado JC et al. Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex. Virchows Arch. 440, 498-504 (2002).
41. Hunt JL, LiVolsi VA, Barnes EL. p63 expression in sclerosing mucoepidermoid carcinomas with eosinophilia arising in the thyroid. Mod. Pathol. 17, 526-529 (2004).
42. Cameselle-Teijeiro J, Varela-Duran J, Sambade C et al. Solid cell nests of the thyroid: light microscopy and immunohistochemical profile. Hum. Pathol. 25, 684-693 (1994).
43. Cameselle-Teijeiro J. Mucoepidermoid carcinoma and solid cell nests of the thyroid. Hum. Pathol. 27, 861-863 (1996).
44. Minagawa A, Iitaka M, Suzuki M et al. A case of primary mucoepidermoid carcinoma of the thyroid: molecular evidence of its origin. Clin. Endocrinol. 57, 551-556 (2002);
45. erratum in Clin. Endocrinol. (Oxf.) 58(1), 114 (2003).
46. Machens A, Holzhausen HJ, Lautenschlager C, Dralle H. The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors. Langenbecks Arch. Surg. 389, 278-282 (2004).
47. Terry JH, St John SA, Karkowski FJ et al. Tall cell papillary thyroid cancer: incidence and prognosis. Am. J. Surg. Pathol. 168(5), 459-461 (1994).
48. Prendiville S, Burman KD, Ringel MD et al. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 122, 352-357 (2000).
49. van den Brekel MW, Hekkenberg RJ, Asa SL, Tomlinson G, Rosen IB, Freeman JL. Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope 107, 254-259 (1997).
50. Taylor T, Specker B, Robbins J et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann. Intern. Med. 129, 622-627 (1998).
51. Apel RL, Asa SL, LiVolsi VA. Papillary Hurthle cell carcinoma with lymphocytic stroma. 'Warthin-like tumor' of the thyroid. Am. J. Surg. Pathol. 19, 810-814 (1995).
52. D'Antonio A, De Chiara A, Santoro M, Chiappetta G, Losito NS. Warthin-like tumour of the thyroid gland: RET/PTC expression indicates it is a variant of papillary carcinoma. Histopathology 36, 493-498 (2000).
53. Xing M, Vasko V, Tallini G et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J. Clin. Endocrinol. Metab. 89, 1365-1368 (1365).
54. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262 (2005).
55. Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399-5404 (2003). BRAF mutation found in anaplastic carcinomas, suggesting a relationship between papillary carcinomas with mutation and dedifferentiation.
56. Basolo F, Giannini R, Monaco C et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am. J. Pathol. 160, 247-254 (2002).
57. Frattini M, Ferrario C, Bressan P et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23, 7436-7440 (2004).
58. Soares P, Trovisco V, Rocha AS et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22, 4578-4580 (2003). BRAF and Ret/PTC are mutually exclusive events, which highlights the importance of the signaling pathway.
59. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63, 4561-4567 (2003).
60. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457 (2003).
61. Hunt JL, Fowler M, Lomago D et al. Tumor suppressor gene allelic loss profiles of the variants of papillary thyroid carcinoma. Diagn. Mol. Pathol. 13, 41-46 (2004).
62. Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod. Pathol. 12, 400-411 (1999).
63. Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 25, 549-561 (1994).
64. Tomoda C, Miyauchi A, Uruno T et al. Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J. Surg. 28, 886-889 (2004).
65. Hirokawa M, Kuma S, Miyauchi A et al. Morules in cribriform-morular variant of papillary thyroid carcinoma: immunohistochemical characteristics and distinction from squamous metaplasia. APMIS 112, 275-282 (2004).
66. Soravia C, Sugg SL, Berk T et al. Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. Am. J. Pathol. 154, 127-135 (1999).
67. Ng SB, Sittampalam K, Goh YH, Eu KW. Cribriform-morular variant of papillary carcinoma: the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. A case report with clinical and molecular genetic correlation. Pathology 35, 42-46 (2003).
68. Kameyama K, Mukai M, Takami H, Ito K. Cribriform-morular variant of papillary thyroid carcinoma: ultrastructural study and somatic/germline mutation analysis of the APC gene. Ultrastruct. Pathol. 28, 97-102 (2004).
69. Cameselle-Teijeiro J, Ruiz-Ponte C, Loidi L, Suarez-Penaranda J, Baltar J, Sobrinho-Simoes M. Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma. Am. J. Clin. Pathol. 115, 486-493 (2001).
70. Miyaki M, Iijima T, Ishii R et al. Molecular evidence for multicentric development of thyroid carcinomas in patients with familial adenomatous polyposis. Am. J. Pathol. 157, 1825-1827 (2000). Adenomatous polyposis coli gene is important in the development of cribriform-morular variant of papillary carcinoma, and biallelic inactivation may be present.
71. Xu B, Yoshimoto K, Miyauchi A et al. Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the β-catenin gene. J. Pathol. 199, 58-67 (2003).
72. Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF, Heffess CS. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 91, 505-524 (2001).
73. Foschini MP, Papotti M, Parmeggiani A et al. Three-dimensional reconstruction of vessel distribution in benign and malignant lesions of thyroid. Virchows Arch. 445, 189-198 (2004).
74. Aida N, Yamada N, Asano G, Tanaka S. 3-D analysis of vascular and capsular invasion in thyroid follicular carcinoma. Pathol. Int. 51, 425-430 (2001).
75. Besic N, Auersperg M, Golouh R. Prognostic factors in follicular carcinoma of the thyroid - a multivariate survival analysis. Eur. J. Surg. Oncol. 25, 599-605 (1999).
76. Hunt JL, Livolsi VA, Baloch ZW et al. A novel microdissection and genotyping of follicular-derived thyroid tumors to predict aggressiveness. Hum. Pathol. 34, 375-380 (2003). Assessing panel of tumor suppressor genes for loss of heterozygosity correlates with tumor aggressiveness.
77. Collini P, Sampietro G, Rosai J, Pilotti S. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch. 442, 71-76 (2003).
78. Gillenwater AM, Weber RS. Thyroid carcinoma. Cancer Treat. Res. 90, 149-169 (1997).
79. Nikiforova MN, Lynch RA, Biddinger PW et al. RAS point mutations and PAX8-PPAR γ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88, 2318-2326 (2003).
80. Garcia-Rostan G, Zhao H, Camp RL et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 21, 3226-3235 (2003).
81. Kroll TG, Sarraf P, Pecciarini L et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289, 1357-1360 (2000).
82. Cheung L, Messina M, Gill A et al. Detection of the PAX8-PPAR γ fusion oncogene in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 88, 354-357 (2003).
83. Nakabashi CC, Guimaraes GS, Michaluart P Jr, Ward LS, Cerutti JM, Maciel RM. The expression of PAX8-PPARγ rearrangements is not specific to follicular thyroid carcinoma. Clin. Endocrinol. 61, 280-282 (2004).
84. French CA, Alexander EK, Cibas ES et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am. J. Pathol. 162, 1053-1060 (2003).
85. Lui WO, Foukakis T, Liden J et al. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene. Oncogene 20, 1-10 (2004).
86. Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab. Invest. 79, 547-55 (1999).
87. Maximo V, Sobrinho-Simoes M. Mitochondrial DNA 'common' deletion in Hurthle cell lesions of the thyroid. J. Pathol. 192, 561-562 (2000).
88. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am. J. Pathol. 160, 1857-1865 (2002).
89. Stoler DL, Datta RV, Charles MA et al. Genomic instability measurement in the diagnosis of thyroid neoplasms. Head Neck 24, 290-295 (2002).
90. Erickson LA, Jalal SM, Goellner JR et al. Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization. Am. J. Surg. Pathol. 25, 911-917 (2001).
91. Tong BC, Ha PK, Dhir K et al. Mitochondrial DNA alterations in thyroid cancer. J. Surg. Oncol. 82, 170-173 (2003).
92. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". Am. J. Surg. Pathol. 8, 655-668 (1984).
93. Sasaki A, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S. Insular component as a risk factor of thyroid carcinoma. Pathol. Int. 46, 939-946 (1996).
94. Chao TC, Lin JD, Chen MF. Insular carcinoma: infrequent subtype of thyroid cancer with aggressive clinical course. World J. Surg. 28, 393-396 (2004).
95. Decaussin M, Bernard MH, Adeleine P et al. Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am. J. Surg. Pathol. 26, 1007-1015 (2002).
96. Hassoun AA, Hay ID, Goellner JR, Zimmerman D. Insular thyroid carcinoma in adolescents: a potentially lethal endocrine malignancy. Cancer 79, 1044-1048 (1997).
97. Pellegriti G, Giuffrida D, Scollo C et al. Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis. Cancer 95, 2076-2085 (2002).
98. Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann. Surg. 231, 329-338 (2000).
99. Takeuchi Y, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid 9, 377-381 (1999).
100. Santoro M, Papotti M, Chiappetta G et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J. Clin. Endocrinol. Metab. 87, 370-379 (2002).
101. Soares P, Trovisco V, Rocha AS et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 444, 572-576 (2004). BRAF mutations are more common in undifferentiated carcinomas than in poorly differentiated tumors.
102. Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann. Surg. 231, 329-338 (2000).
103. Carda C, Ferrer J, Vilanova M, Peydro A, Llombart-Bosch A. Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases. Virchows Arch. 446, 46-51 (2005).
104. Miettinen M, Franssila KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum. Pathol. 31, 1139-1145 (2000).
105. Bejarano PA, Nikiforov YE, Swenson ES, Biddinger PW. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Appl. Immunohistochem. Mol. Morphol. 8, 189-194 (2000).
106. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann. Oncol. 11, 1083-1089 (2000).
107. Xing M, Vasko V, Tallini G et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J. Clin. Endocrinol. Metab. 89, 1365-1368 (2004).
108. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol. 17, 1359-1363 (2004).
109. Sheils OM, O'Leary JJ, Sweeney EC. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR. J. Pathol. 192, 32-36 (2000).
110. Capella G, Matias-Guiu X, Ampudia X, de Leiva A, Perucho M, Prat J. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction- fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn. Mol. Pathol. 5, 45-52 (1996).
111. Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am. J. Surg. Pathol. 27, 1559-1564 (2003).
112. Frisk T, Foukakis T, Dwight T et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer 35, 74-80 (2002).
113. Kadota M, Tamaki Y, Sekimoto M et al. Loss of heterozygosity on chromosome 16p and 18q in anaplastic thyroid carcinoma. Oncol. Rep. 10, 35-38 (2003).
114. La Perle KM, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am. J. Pathol. 157, 671-677 (2000).
115. Hirokawa M, Carney JA, Goellner JR et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am. J. Surg. Pathol. 26, 1508-1514 (2002).
116. Saxen E, Franssila K, Bjarnason O, Normann T, Ringertz N. Observer variation in histologic classification of thyroid cancer. Acta Pathol. Microbiol. Scand. [A] 86A, 483-486 (1978).
117. Lloyd RV, Erickson LA, Casey MB et al. Observer variability in the diagnosis of follicular variant of papillary thyroid carcinoma. Am. J. Surg. Pathol. 28, 1336-1340 (2004). There is significant interobserver variability in the diagnosis of follicular variant of papillary carcinoma, which highlights the need for better tumor markers.